$200,000 Initial Cash Committed for Relief Effort, FedEx and Healthcare Companies Step Up as Emergency Unfolds
GOLETA, Calif., April 6, 2017 /360WiseNews/ — Direct Relief today committed an initial $200,000 in cash and made available $32 million in medical resources for relief and recovery efforts in Colombia and Peru, where historic flooding and mudslides have claimed hundreds of lives and displaced hundreds of thousands more.
Today’s commitment follows several emergency air shipments from Direct Relief of medical aid totaling $7.8 million and 38 tons (76,000 lbs.).
“People in Peru and Colombia are facing severe risks in the wake of devastating storms, and Direct Relief is extending support to our capable partner organizations providing frontline care in a still unfolding, complex emergency,” said Direct Relief President and CEO Thomas Tighe.
Water sources often become compromised after serious flooding, which can lead to a host of health issues. Cholera and other diseases related to poor sanitation pose additional threats to public health. Neglected tropical diseases including trachoma, soil-transmitted pathogens, and various bacterial and parasitic infections also present risks to people in the area.
Bolstered by strong support from corporate partners that include AbbVie, Allergan, Actavis, Baxter, BD, Boehringer Ingelheim, Teva, Pfizer, and Unilever, Direct Relief is sending antibiotics, antivirals, rehydration supplies and hygiene kits. FedEx has provided emergency airlift support.
In Peru, Direct Relief is assisting four partner organizations providing emergency services and conducting medical missions in close coordination with the Peruvian Ministry of Health. Patrulla Area Colombiana (PAC, a Colombian NGO of pilots and medics), Asociacion Paz Peru, Socios en Salud (Partners in Health), and Asociacion Vida Peru have received and distributed $3.9 million of essential medications and supplies totaling 17.5 tons to eight hard-hit regions: Lima, Huarmey, Piura, Pedregal Alto, Simbila, Tumbes, Casma, and Arequipa. Direct Relief also is funding the deployment of 20 medical personnel to Piura to provide medical care and deliver seven tons of medicine and medical supplies. Keep Reading
NEW YORK, April 6, 2017 /360WiseNews/ — The rehabilitation equipment market is projected to reach USD 14.91 billion by 2021 from USD 9.86 billion in 2016, at a CAGR of 8.6% during 2016-2021. The market for rehabilitation equipment is expanding due to the increasing incidence of disabilities resulting from non-communicable diseases, favorable healthcare reforms, and rapid growth in the geriatric population, coupled with the rising prevalence of chronic diseases. On the other hand, the high cost & maintenance expense of rehabilitation equipment are limiting the growth of the market to a certain extent.
Read the full report: http://www.reportlinker.com/p04814913/Rehab-Equipment-Market-by-Type-Mobility-Wheelchair-Assist-Device-Body-Support-Lift-Sling-Exercise-Upper-Lower-Body-Living-Aids-Reading-Writing-Application-Physiotherapy-OT-End-User-Hospital-Clinic-Home-Care-Forecasts-to.html
Based on type, the rehabilitation equipment market is segmented mobility equipment, body support devices, exercise equipment, and daily living aids. The mobility equipment segment is expected to grow at the highest CAGR during 2016–2021. The growth in this segment is attributed to the increasing the number of elderly people suffering from orthopedic impairments which is creating a demand for mobility equipment worldwide. Moreover, the increasing number of disabled people and growing awareness on safety measures in handling patients are driving the demand for mobility equipment. Keep Reading
NEW YORK, April 6, 2017 /360WiseNews/ —
The global non-invasive prenatal testing (NIPT) market is projected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021.
The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.
Read the full report: http://www.reportlinker.com/p04814911/Non-Invasive-Prenatal-Testing-NIPT-Market-by-Instruments-Ultrasound-NGS-PCR-Microarray-Consumables-Method-FCMB-cf-DNA-Application-Trisomy-Microdeletion-Genetics-Rh-factor-End-User-Hospital-Diagnostic-Labs-Global-Forecast-to.html
By product, the non-invasive prenatal testing market is segmented into consumables and instruments. In 2016, the consumables segment accounted for the largest share of the market. The high demand due to the recurring requirement of consumables as compared to instruments is a key driver for the growth of this product segment.
On the basis of method, the market is segmented into ultrasound detection, biochemical screening tests, fetal cells in maternal blood tests, and cell-free DNA in maternal plasma tests. The ultrasound detection segment dominated the market in 2016. However, the cell-free DNA in maternal plasma tests segment is expected to grow at the highest CAGR. This is mainly attributed to the increasing demand for cf-DNA based techniques in NIPT testing and rising government initiatives to provide prenatal services.
On the basis of application, the market is segmented into Trisomy, microdeletion syndrome, and other applications. Trisomy commands the largest and fastest-growing application segment of the global market in 2016. This is attributed to factors such as increasing maternal age and rising incidence of chromosomal abnormalities. Keep Reading
NEW YORK, April 5, 2017 /360WiseNews/ — Repeated cycles of weight loss and gain may be linked to higher risk for stroke, heart attack, and death in people with pre-existing coronary artery disease, according to a study published online April, 5 in the New England Journal of Medicine.
Led by researchers at NYU Langone Medical Center, the study was the first to measure the effect of “weight cycling” on health outcomes in people with pre-existing heart disease. People with the largest weight changes were found to experience 136 percent more strokes, 117 percent more heart attacks, and 124 percent more deaths than those with the smallest shifts in weight.
Those in the high-fluctuation group had weight changes as large as 3.9 kilograms (or roughly 8.6 pounds), while weight varied by around 0.9 kilograms (just under 2 pounds) in the group with the smallest shifts in weight.
“Our findings suggest that we need to be concerned about weight fluctuation in this group that is already at high risk due to coronary disease,” says lead study author Sripal Bangalore, MD, director of the cardiovascular outcomes group in the Cardiovascular Clinical Research Center at NYU Langone.
“Even though this analysis was not designed to find out the causes of increased risk with body weight fluctuations, we need to examine how we can help Americans keep weight off, rather than having it go up and down,” says Bangalore, an associate professor of medicine in the Leon H. Charney Division of Cardiology. Keep Reading
KYOTO, Japan, March 30, 2017 /360WiseNews/ — OMRON Corporation (TSE: 6645, ADR: OMRNY) will introduce on April 3, 2017, “E5CD/E5ED Temperature Controllers” to automatically adjust temperature parameters of heaters and others using AI that used to be done by skilled workers at production sites and “E52-CA xx AY S xx Temperature Sensors for Packaging Machines.”
OMRON will showcase the “E5CD/E5ED Temperature Controllers” and “E52-CA xx AY S xx Temperature Sensors for Packaging Machines” at the “2017 International Food Machinery & Technology Exhibition” to be held at Tokyo Big Sight from June 13 to 16.
(Photo1: E5CD/E5ED Temperature Controllers
(Photo2: E52-CA xx AY S xx Temperature Sensors for Packaging Machines
The newly released E5CD/E5ED Temperature Controllers include OMRON’s unique temperature adjustment algorithm. The E5CD and E5ED automatically adjust temperature parameters that until now skilled workers have been doing based on experience and intuition in response to production status changes, including production items and materials compounding.
At today’s production sites, multi-product production makes manufacturing highly complicated. This accelerates production transfer to emerging countries for optimally located production, leading to product defects and lower productivity resulting from worker skill shortage. Especially in the molding and packaging processes, temperature adjustment required when production items change is not properly done. To avoid quality loss that is caused by temperature, the equipment operation speed slows down and inspection work takes more time at the expense of productivity. Keep Reading
SHANGHAI, March 30, 2017 /360WiseNews/ — WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec Affiliate, today announced that it had received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm.
Asia-Pacific Bioprocessing Excellence Awards aims to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and best practices in manufacturing, WuXi Biologics has been recognized for its outstanding performance that facilitating biomanufacturing excellence at enhanced speed, reduced cost and superior quality.
As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which is the first in China that met cGMP standards of the United States, the European Union, and China. In 2015, WuXi began construction of world’s largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia’s largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners. Keep Reading